Introduction
============

The limb skeleton is derived via the process of endochondral ossification, which begins with the condensation of mesenchymal progenitor cells within the developing limb-buds. Cells within condensations undergo chondrogenesis, creating a cartilage template of the skeletal elements, while cells at the periphery known as perichondrial cells ultimately differentiate into osteoblasts that form bone. Chondrocytes of the developing skeletal elements proliferate with round disorganized chondroctyes near the epiphyses giving rise to flattened chondrocytes organized in columns near the metaphyses. This organization provides directionality to the longitudinal expansion of cartilage rudiments. As chondrocytes approach the center of the elements, they exit the cell cycle and begin the process of hypertrophic differentiation. Chondrocyte hypertrophy is a key step during endochodral bone development where chondrocytes dramatically alter their morphology and size to generate a mineralizing cartilage matrix. Hypertrophic chondrocytes also secrete molecules important in inducing osteoblastogenesis, recruiting vascular tissue to the primary ossification center, and aiding in the process of replacing the mineralized cartilage with bone.^[@bib1]^ When this process is perturbed, chondrodysplasias and known cartilage and skeletal disorders arise.

Specific transcription factors are responsible for directing the differentiation pattern of chondrocytes and osteoblasts during endochondral ossification. SOX9 is a transcription factor known to be a master regulator of chondrogenesis and the differentiated chondrocyte phenotype.^[@bib2]^ In humans, heterozygous mutations of *Sox9* results in campomelic dysplasia, a lethal developmental disorder characterized by generalized hypoplasia of endochondral bones and XY sex reversal.^[@bib3],[@bib4]^ In mice and humans, haploinsufficiency of *Sox9* is lethal shortly after birth and phenocopies many of the skeletal anomalies present in campomelic dysplasia.^[@bib5]^ A study of *Sox9*^−/−^ chimeric mice, as well as a study using *Prx1Cre* to selectively inactivate *Sox9* floxed alleles within the skeletogenic mesenchyme has identified *Sox9* as necessary for the formation of mesenchymal condensations.^[@bib6],[@bib7]^ SOX9 activation of chondrocyte-specific genes is partially mediated through its activation of two other distantly related members of the SOX family, SOX5 and SOX6.^[@bib8]^ The three proteins, together, have been shown to activate numerous cartilage-specific extracellular matrix genes, including *Col2a1*, *Col11a2*, *Matrilin-1*, *Col27a1*, and *Agc1*^[@bib2]^ that maintain the differentiated chondrocyte environment. Recent studies have also shown that over-expression of *Sox9* in hypertrophic chondrocytes results in delayed terminal chondrocyte maturation and cartilage matrix turnover, suggesting a specific role in regulating chondrocyte hypertrophy.^[@bib9]^ While previous studies have shown negative regulation of *Sox9* by the β-catenin signaling pathway results in accelerated chondrocyte hypertrophy^[@bib10]^ and positive regulation by the TGFb/BMP signaling pathways induces chondrogenesis,^[@bib11],[@bib12]^ the precise genetic mechanisms regulating *Sox9* gene expression during cartilage development remain ill-defined.

Recent studies have identified the Notch signaling pathway as a potential regulator of *Sox9* in chondrocytes. Briefly, Notch signaling is initiated when a ligand of the Delta/Jagged families bind to a Notch receptor (NOTCH1-4). Binding initiates a series of cleavage events, culminating in gamma-secretase mediated release of the intracellular portion of the Notch receptor, known as the Notch Intracellular Domain (or NICD). Once released, NICD translocates to the nucleus where it binds the transcriptional repressor RBPjk, converting it to a transcriptional activator. A transcriptionally active complex composed, in part, of NICD, RBPjk and MAML drives expression of target genes, such as those of the *Hes*/*Hey* gene family.^[@bib13],[@bib14]^ In the absence of NICD, RBPjk recruits the co-repressors SMRT and SHARP resulting in a suppression of transcription.^[@bib15],[@bib16]^ Recently, two studies have shown that over-expression of NICD, using either the *Prx1Cre* to target the skeletogenic mesenchyme or the *Col2Cre* to target chondro-osteoprogenitor cells, results in inhibition of condensation formation, significantly reduced levels of *Sox9*, and, ultimately, an inability to form skeletal elements.^[@bib17],[@bib18]^ These mutants are markedly similar to those observed in mutant embryos lacking *Sox9* expression in the skeletogenic mesenchyme.^[@bib6]^ Furthermore, mutant mice with over-expression of *Sox9* in hypertrophic chondrocytes using the *Col10a1* promoter^[@bib9]^ are histologically very similar to previously reported mice lacking various components of the Notch signaling pathway, including the *Notch1* and *Notch2* receptors and *Rbpjk*.^[@bib19],[@bib20]^ Interestingly, loss of *Rbpjk* in chondro-osteoprogenitor cells leads to increased levels of *Sox9* gene expression in growth plate chondrocytes, specifically in the hypertrophic cells, while over-expression of NICD leads to decreased *Sox9* expression throughout the growth plate.^[@bib18]^ These data suggest a possible mechanism, by which RBPjk-dependent Notch signaling is required to modulate *Sox9* expression during cartilage development and chondrocyte hypertrophy.

To examine the genetic interaction between RBPjk-dependent Notch signaling and *Sox9* we analyzed tissue-specific *Rbpjk* mutant (*Prx1Cre;Rbpjk^f/f^*), *Rbpjk* mutant/*Sox9* haploinsufficient (*Prx1Cre;Rbpjk^f/f^;Sox9^f/+^*), and control embryos for alterations in chondrocyte hypertrophy and cartilage growth. Additionally, chondrogenic cell lines were used to assess the specific mechanisms by which Notch signaling regulates the *Sox9* promoter. The cartilage and molecular phenotypes observed in our genetic studies combined with our *in vitro* molecular data demonstrate that RBPjk-dependent Notch signaling coordinates the onset of chondrocyte maturation and cartilage growth largely via indirect regulation of *Sox9*.

Materials and methods
=====================

Mouse strains
-------------

All mouse strains including *Prx1Cre*, *Rbpjk^f/f^*, and *Sox9^f/f^* are as previously described.^[@bib5],[@bib21],[@bib22]^ *Prx1Cre* and *Sox9^f/f^* mice were obtained from the Jackson Laboratory; *Rbpjκ^f/f^* mice were a generous gift from Dr. Tasuku Honjo (Kyoto Graduate School of Medicine, Japan). Embryos of the genotypes *Prx1Cre;Rbpjk^f/+^*, *Prx1Cre;Rbpjk^f/+^;Sox9^f/+^*, *Prx1Cre;Rbpjk^f/f^*, *Prx1Cre;Rbpjk^f/f^;Sox9^f/+^*, and Cre-negative littermate controls were produced in Mendelian ratios to be analyzed from E14.5 to E18.5. All animal studies were performed in accordance with the guidelines set forth by the Institutional Animal Care and Use Committee.

Analyses of mouse embryos
-------------------------

Embryonic tissues were harvested at E14.5--E18.5, fixed in 10% neutral buffered formalin, decalcified in 14% EDTA, processed, and embedded in paraffin prior to sectioning at 6 μm. Alcian Blue/Hematoxylin/Orange G (ABH/OG) staining was performed according to standard methodologies. *In situ* hybridization was performed as described previously,^[@bib17],[@bib19],[@bib20],\ [@bib23],[@bib24]^ using ^35^S-labeled riboprobes. Immunohistochemistry for SOX9 was performed using the Vectastain Elite Rabbit IgG Kit (Vector) and Santa Cruz Biotechnology SOX9 antibody (sc20095). SOX9 antibody was prepared in 4% normal goat serum using a 1:200 dilution without antigen retrieval. Color reaction was performed using Vector ImmPACT DAB (Vector); sections were counterstained with hematoxylin (Zymed).

Whole-mount skeletal staining of embryos was performed as previously described.^[@bib17],[@bib25],[@bib26]^

*Sox9* luciferase assays
------------------------

Forty-eight hours before transfection, ATDC5 cells (RIKEN) were plated in 24-well plates. ATDC5 cells were maintained at 37 °C with 5% CO~2~ in DMEM/F12 (1:1) supplemented with 5% fetal bovine serum, and 1% penicillin/streptomycin. Transfections were completed using FuGENE HD (Promega) with 600 ng of Flag or NICD1, 200 ng *Sox9*-pGL3-promoter DNA constructs, and 8 ng *Renilla* (Promega). Flag and NICD1 constructs were transfected first for 24 hours before adding the respective *Sox9*-pGL3 constructs and *Renilla* for 24 additional hours. After the 48 hours of transfections, cellular extracts were collected using the lysis buffer in the dual-luciferase assay (Promega). Firefly luciferase activity was assessed using 20 μL or microliter of cellular extracts followed by immediate analysis of *Renilla* luciferase activity. Analysis of the data was performed by normalizing *Sox9*-pGL3 luciferase activity to *Renilla* luciferase activity; normalized luciferase activity was then normalized to the Flag control of the respective *Sox9*-pGL3 constructs. Luciferase assays were performed in triplicate and repeated three times. Statistical analysis was performed using a two-tailed, unpaired *t*-test.

*In vitro* Notch activation and protein synthesis inhibition Six-well tissue culture plates were coated with RetroNectin (Takara) solution (20 μg·mL^−1^ in 1X PBS, 1 mL per well) at 4 °C overnight while gently rocking. The following day, each well was blocked with 1 mL 2% BSA (Sigma) for 30 minutes at room temperature and briefly washed with 1X PBS. The plate was then coated with anti-IgG (Sigma) (10 μg·mL^−1^ in 1X PBS, 1 mL per well) at 4 °C overnight while gently rocking. The following day, each well was blocked with 1 mL 2% BSA for 30 minutes at room temperature and briefly washed with 1X PBS. The plate was next coated with either IgG (Sigma) (10 μg·mL^−1^ in 1X PBS, 1 mL per well) or Recombinant JAG1 protein (R&D Systems) (10 μg·mL^−1^ in 1X PBS, 1 mL per well) at 4 °C overnight while gently rocking. The following day, each well was blocked with 1 mL 2% BSA for 30 minutes at room temperature and briefly washed with 1X PBS. Coated plates were air dried for 1 hour in the tissue culture hood, sealed with parafilm and stored at 4 °C until use. ATDC5 cells were seeded onto the IgG- or JAG1-coated plates at a density of 500 000 cells per well in ITS media ± the protein synthesis inhibitor, cycloheximide (10 μg·mL^−1^) (Sigma). RNA was harvested at 0, 2, 4, and 8 hours after seeding and quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed to measure levels of *Hes1*, *Hey1*, and *Sox9* gene expression.

Results
=======

Loss of *RBPjk* leads to inappropriate expression of SOX9 in hypertrophic chondrocytes
--------------------------------------------------------------------------------------

In previous studies, we have demonstrated that RBPjk-dependent Notch signaling is necessary for normal onset of chondrocyte maturation as well as terminal hypertrophy.^[@bib20]^ In these studies, the *Prx1Cre* transgene was used to selectively target removal of *Rbpjk* from the skeletogenic mesenchyme of the developing limb. While a clear role for RBPjk-dependent Notch signaling during chondrocyte maturation was established, the downstream mechanisms have not been determined. Previous studies have shown that *Sox9* is expressed in the epiphyseal resting and proliferating chondrocytes but not in the hypertrophic chondrocytes.^[@bib27]^ Interestingly, immunohistochemistry for SOX9 reveals persistent, inappropriate expression of SOX9 protein within deeper zones of the hypertrophic region in *Prx1Cre;Rbpjk^f/f^* mutants, compared to littermate controls ([Figure 1a and b](#fig1){ref-type="fig"}). This is consistent with data showing that over-expression of NICD in chondro-osteoprogenitor and mesenchymal progenitor cells leads to reduced *Sox9* gene expression in cartilage and limb-bud mesenchyme, respectively.^[@bib18]^ Conversely, when RBPjk is removed, *Sox9* gene expression is elevated in all chondrocytes.^[@bib18]^ Collectively, these data suggest a possible mechanism for RBPjk-dependent Notch signaling regulation of chondrocyte hypertrophy via *Sox9* regulation.

*Sox9* haploinsufficiency rescues delays in onset of chondrocyte hypertrophy due to loss of *Rbpjk*
---------------------------------------------------------------------------------------------------

To begin to understand the genetic interactions between RBPjk-dependent Notch signaling and *Sox9*, we removed a single copy of *Sox9* in the background of *Rbpjk* mutants. For completeness, the breeding strategy allowed for the generation of the following genotypes: Cre-negative controls, *Rbpjk* heterozygous (*Prx1Cre;Rbpjk^f/+^*), double heterozygous (*Prx1Cre;Rbpjk^f/+^;Sox9^f/+^*), *Rbpjk* mutants (*Prx1Cre;Rbpjk^f/f^*), and *Rbpjk* mutant/*Sox9* haploinsufficient (*Prx1Cre;Rbpjk^f/f^;Sox9^f/+^*) embryos.

Histological examination of E14.5 embryos with ABH/OG staining ([Figure 2](#fig2){ref-type="fig"}) revealed the expected delay in onset of hypertrophy in *Rbpjk* mutant embryos, as indicated by the shorter hypertrophic zone ([Figure 2a2](#fig2){ref-type="fig"}) compared to littermate controls ([Figure 2a1](#fig2){ref-type="fig"}). Interestingly, *Rbpjk* mutant/*Sox9* haploinsufficient embryos ([Figure 2a4](#fig2){ref-type="fig"}) revealed a longer hypertrophic zone compared to controls, indicating acceleration in chondrocyte hypertrophy. The longer hypertrophic zone was also seen in double heterozygous embryos ([Figure 2a3](#fig2){ref-type="fig"}), suggesting that *Sox9* haploinsufficiency is sufficient to accelerate chondrocyte hypertrophic differentiation. To ensure that the accelerated hypertrophic phenotype was due to *Sox9* haploinsufficiency and not a result of double heterozygosity of *Rbpjk* and *Sox9*, we examined *Sox9* heterozygous embryos (*Prx1Cre;Sox9^f/+^*). At E14.5, loss of a single allele of *Sox9* results in a longer hypertrophic zone compared to littermate controls ([Figure 2a5 and a6](#fig2){ref-type="fig"}). Finally, quantitative analysis of the hypertrophic zone revealed a significantly shorter hypertrophic zone in *Rbpjk* mutants compared to controls, while the *Rbpjk* mutant/*Sox9* haploinsufficient hypertrophic zones were significantly longer than both controls and *Rbpjk* mutants and were similar to *Rbpjk*/*Sox9* double heterozygous mice ([Figure 2b1](#fig2){ref-type="fig"}). Removal of a single *Rbpjk* allele in the *Sox9* haploinsufficient background had no significant effect on the *Sox9* heterozygous change in hypertrophy ([Figure 2b1 and b2](#fig2){ref-type="fig"}). Similar histological changes in the onset of chondrocyte hypertrophy were observed in all elements examined from both forelimb and hindlimb (data not shown).

Cartilage elements of the limb skeleton were further analyzed for common markers of chondrocyte hypertrophy using *in situ* hybridization ([Figure 3](#fig3){ref-type="fig"}). As observed in [Figure 2](#fig2){ref-type="fig"}, histological analysis by ABH/OG staining revealed a smaller hypertrophic zone in *Rbpjk* mutant embryos, but a larger hypertrophic zone in *Rbpjk* mutant/*Sox9* haploinsufficient embryos ([Figure 3a--c](#fig3){ref-type="fig"}). As we previously reported,^[@bib20]^ molecular analysis using *in situ* hybridization revealed significantly smaller *Ihh* and *Col10a1* domains in *Rbpjk* mutant embryos compared to controls ([Figure 3d, e, g, h](#fig3){ref-type="fig"}). Furthermore, molecular analysis for *Mmp13* showed a small number of cells expressing *Mmp13* in the control sections ([Figure 3j](#fig3){ref-type="fig"}, orange circle), while no *Mmp13* expressing cells are detected in *Rbpjk* mutant sections ([Figure 3k](#fig3){ref-type="fig"}). Conversely, *in situ* hybridization for *Ihh* and *Col10a1* reveals larger expression domains in *Rbpjk* mutant/*Sox9* haploinsufficient embryos, and a wide domain of *Mmp13* expressing cells ([Figure 3f, i, l](#fig3){ref-type="fig"}). These data indicate that during chondrocyte hypertrophy, *Sox9* is likely downstream of RBPjk-dependent Notch signaling such that a reduction in *Sox9* expression in *Rbpjk* mutants largely corrects or over-corrects the delay in chondrocyte hypertrophy.

Cartilage element shortening due to *Sox9* haploinsufficiency is rescued by loss of *Rbpjk*
-------------------------------------------------------------------------------------------

Examination of ABH/OG stained full-length tibia sections ([Figure 4a](#fig4){ref-type="fig"}) revealed that skeletal elements of the *Rbpjk* mutants ([Figure 4a2](#fig4){ref-type="fig"}), the double heterozygous ([Figure 4a3](#fig4){ref-type="fig"}) and the *Rbpjk* mutant/*Sox9* haploinsufficient embryos ([Figure 4a4](#fig4){ref-type="fig"}) were all significantly smaller than littermate controls and displayed bowed skeletal elements ([Figure 4a1](#fig4){ref-type="fig"}). Double heterozygous mutants displayed the shortest skeletal elements, which were comparable to *Sox9* heterozygous mutant embryos (*Prx1Cre;Sox9^f/+^*) in both length and curvature of the elements ([Figure 4a3 and 4b2](#fig4){ref-type="fig"}). Quantification revealed that the tibias of all three mutants were significantly shorter than controls, and that the double heterozygous were significantly shorter than *Rbpjk* mutants or the *Rbpjk* mutant/*Sox9* haploinsufficient embryos ([Figure 4c](#fig4){ref-type="fig"}). Interestingly, removal of both *Rbpjk* floxed alleles in the *Sox9* haploinsufficient background restores tibia length equivalent to the *Rbpjk* mutant size, although does not correct the curvature or bowing of the *Sox9* heterozygous or double heterozygous mutants. Furthermore, BrdU analyses showed no significant difference in chondrocyte proliferation between all mutant genotypes (data not shown), suggesting the rescued length in *Rbpjk* mutant/*Sox9* haploinsufficient embryos as compared to double heterozygous or *Sox9* heterozygous mutants is likely due to alterations in hypertrophic differentiation. Collectively, these data suggest that complete removal of Rbpjk-dependent Notch signaling elevates *Sox9* expression to a level that can counteract some of the chondrogenic effects oberserved in *Sox9* happloinsuficient mutant mice.

*Sox9* haploinsufficiency does not rescue delays in chondrocyte terminal hypertrophy due to loss of *Rbpjk*
-----------------------------------------------------------------------------------------------------------

We further analyzed limbs from E18.5 embryos in a similar manner to those from E14.5. ABH/OG staining of proximal tibia growth plates revealed the long hypertrophic zone characteristic of the delayed terminal chondrocyte hypertrophy observed in *Rbpjk* mutants, compared to controls ([Figure 5a1 and a2](#fig5){ref-type="fig"}). Interestingly, the double heterozygous embryos appeared to have relatively normal growth plates without any significant change in length of the hypertrophic zone, however, the overall size of the cartilage growth plate was slightly smaller than controls ([Figure 5a3](#fig5){ref-type="fig"}). Interestingly, the growth plate and hypertrophic zone of the *Rbpjk* mutant/*Sox9* haploinsufficient embryos phenocopied that of *Rbpjk* mutants, specifically in regard to the expanded hypertrophic zone ([Figure 5a2 and a4](#fig5){ref-type="fig"}). *In situ* hybridization for chondrocyte hypertrophy markers, *Ihh*, *Col10a1*, and *Mmp13*, was performed on E18.5 tibia sections. Analysis of the proximal growth plate revealed expanded domains of *Ihh*, *Col10a1*, and *Mmp13* in both the *Rbpjk* mutants and *Rbpjk* mutant/*Sox9* haploinsufficient embryos compared to controls, while the double heterozygous embryos reveal domains similar in size to controls with a mild enhancement in *Mmp13* ([Figure 5a4--a12](#fig5){ref-type="fig"}). Consistent with the results observed in [Figure 1](#fig1){ref-type="fig"}, IHC results demonstrate that SOX9 protein persists deeper into the hypertrophic zone of *Rbpjk* mutants due to the enhanced *Sox9* expression as compared to controls ([Figure 5b1 and b2](#fig5){ref-type="fig"}). Interestingly, while SOX9 persistence within the hypertrophic chondrocytes was reduced in *Rbpjk* mutant/*Sox9* haploinsufficient embryos compared to *Rbpjk* mutants, the progression through terminal chondrocyte hypertrophy was still delayed (identified by the expanded hypertrophic zones) ([Figure 5b2 and b3](#fig5){ref-type="fig"}). These data indicate that RBPjk-dependent Notch signaling regulation of terminal chondrocyte hypertrophy and cartilage matrix turnover may function independent of *Sox9* transcriptional control.

Notch mediated suppression of *Sox9* requires secondary effectors
-----------------------------------------------------------------

The Notch signaling pathway has been shown to be an important regulator of *Sox9*, although the mechanism of this regulation is controversial. Here, we performed a rigorous analysis of the known *Sox9* promoter and *Sox9* gene expression in the context of Notch signaling activation. To achieve this, we first utilized *Sox9* luciferase constructs containing various sizes of the *Sox9* promoter. As shown in [Figure 6a](#fig6){ref-type="fig"}, the only construct containing RBPjk consensus sequences is the 6.8 kb known promoter fragment. Using ATDC5 cells, we co-transfected the 6.8 kb (6.8 kb WT) construct with either Flag (control) or NICD1 over-expression plasmids. As expected, the over-expression of NICD1 suppressed *Sox9* luciferase activity ([Figure 6b](#fig6){ref-type="fig"}). According to Chen *et al.*, the RBPjk consensus sequence, located 3 kb upstream of the transcriptional start site, is the site significantly enriched of the NICD/RBPjk complex.^[@bib28]^ To determine if this site is responsible for the suppression of *Sox9*, we made point mutations designed to prevent the binding of RBPjk to its consensus sequence (TGGGAA to TCCGAA).^[@bib29]^ After co-transfecting the 6.8 kb mutant (6.8 kb MT) construct with Flag or NICD1, we observed suppression of *Sox9* luciferase activity despite the RBPjk mutation ([Figure 6b](#fig6){ref-type="fig"}). To rule out the possibility that NICD may be binding to another RBPjk site in the 6.8 kb promoter region, we utilized a *Sox9* luciferase construct containing only 1 kb of promoter sequence upstream of the transcriptional start site, which does not contain any RBPjk binding sites. We co-transfected the 1 kb *Sox9* construct with Flag or NICD1, and observed a similar level of suppression as seen with the 6.8 kb construct ([Figure 6c](#fig6){ref-type="fig"}). Interestingly, most or all of the Notch-mediated suppression of *Sox9* luciferase activity was lost when the promoter fragments were reduced to contain only 0.5 kb to 0.32 kb of the *Sox9* promoter ([Figure 6c](#fig6){ref-type="fig"}). These data provide evidence that the NICD1 suppression of *Sox9* likely occurs via secondary effectors and does not utilize the RBPjk binding sites in a suppressive manner.

To elucidate the mechanism of the Notch suppression of *Sox9*, we used a bioinformatic approach to analyze the 1 kb upstream fragment (TRANSFAC; Biobase). Interestingly, we located a conserved N-box consensus sequence (CACCAG) ([Figure 6a](#fig6){ref-type="fig"}) at −681 to −676. The N-box is one of two known binding sites of the HES/HEY family of transcription factors. HES/HEY factors are well characterized as downstream Notch target genes. Upon binding to the N-box, HES/HEY factors will recruit co-repressors inhibiting gene transcription.^[@bib30]^ Additionally, it has been shown in the developing limb that Notch signaling can induce *Hes/Hey* gene expression.^[@bib17]^ Interestingly, the 0.5 kb and 0.32 kb *Sox9* luciferase constructs utilized in [Figure 6c](#fig6){ref-type="fig"} both lack the identified N-box. These constructs are deficient in suppressing *Sox9* luciferase expression suggesting that Notch suppression of *Sox9* is mediated via secondary effectors that likely include one or more of the HES/HEY factors.

To further determine whether Notch inhibits *Sox9* expression directly or via downstream target gene activation, we initiated Notch signaling in ATDC5 cells using Jagged1 (JAG1) coated plates and assessed Notch-induced gene expression ([Figure 6d](#fig6){ref-type="fig"}). Cultures were maintained in the presence or absence of the protein synthesis inhibitor, cycloheximide, in order to assess whether translation of downstream Notch target genes is required for *Sox9* gene regulation. RNA was isolated from cultures at 0, 2, 4, and 8 hours of culture, and quantitative RT-PCR was performed to measure levels of the established Notch target genes, *Hes1* and *Hey1*,^[@bib31]^ as well as *Sox9*. The culture of ATDC5 cells on JAG1 coated plates versus IgG coated control plates leads to significant up-regulation of both *Hes1* and *Hey1* gene expression across all time points ([Figure 6d1--d4](#fig6){ref-type="fig"}). When we conducted this experiment in the presence of cycloheximide ([Figure 6d2 and d4](#fig6){ref-type="fig"}), similar levels of *Hes1* and *Hey1* up-regulation were observed indicating that both *Hes1* and *Hey1* transcription are directly activated by RBPjk-dependent Notch signaling, as has been previously reported.^[@bib31]^ Interestingly, when we examine *Sox9* transcriptional regulation in the absence of cycloheximide, we see an initial mild up-regulation of *Sox9* gene expression at 2 hours, but then see a sustained inhibition of *Sox9* expression at 4 and 8 hours ([Figure 6d5](#fig6){ref-type="fig"}). When we assess Notch signaling effects on *Sox9* gene expression in the presence of cycloheximide, we find the same but significant mild up-regulation of *Sox9* at 2 hours. However, the inhibition of *Sox9* gene expression seen in the absence of cycloheximide at 4 and 8 hours ([Figure 6d5](#fig6){ref-type="fig"}) is lost when ATDC5 cells are cultured in the presence of cycloheximide and JAG1 activation ([Figure 6d6](#fig6){ref-type="fig"}). These results indicate that Notch signaling can initially promote *Sox9* gene expression directly through the NICD/RBPjk transcriptional activating complex, but the inhibition of *Sox9* requires the translation of Notch-dependent target genes.

Discussion
==========

Our previous work identified RBPjk-dependent Notch signaling as a necessary regulator of both the onset of chondrocyte hypertrophy and the progression to terminal chondrocyte maturation, although the mechanism remains unknown.^[@bib20]^ Here we have provided conclusive genetic evidence linking RBPjk-dependent Notch signaling to the regulation of *Sox9* expression and chondrocyte hypertrophy. In *Rbpjk* mutant embryos, haploinsufficiency of *Sox9* was able to rescue the delays in onset of chondrocyte hypertrophy, but had little if any impact on delayed progression to terminal chondrocyte maturation and cartilage matrix turnover. Interestingly, limb length reductions characteristic of *Sox9* haploinsufficiency were partially resolved when RBPjk-dependent Notch signaling was completely removed, suggesting that a delicate regulation and balance of *Sox9* expression is required to coordinate chondrocyte hypertrophy and cartilage growth. Furthermore, our *in vitro* results demonstrate the ability of Notch signaling to acutely enhance *Sox9* expression likely through direct RBPjk-dependent regulation, while continuous Notch signaling suppresses *Sox9* via secondary effectors.

SOX9 is well established as the master regulator of chondrogenesis and a factor required for the maintenance of the immature chondrocyte phenotype,^[@bib5; @bib6; @bib7],[@bib32],[@bib33]^ and thus a potential target of RBPjk-dependent Notch function in cartilage development. Our work, as well as others, has shown that *Sox9* is normally down-regulated in hypertrophic chondrocytes,^[@bib27]^ indicating that *Sox9* down-regulation is required for the onset of hypertrophy. A recent study has specifically addressed this by using a *BAC-Col10a1* promoter to drive continuous expression of *Sox9* in hypertrophic chondrocytes.^[@bib9]^ Maintenance of SOX9 within hypertrophic chondrocytes results in an elongated zone of hypertrophic chondrocytes at E18.5, strikingly similar to the elongated hypertrophic zone caused by the delayed progression to terminal chondrocyte maturation observed in Notch mutant embryos.^[@bib19],[@bib20]^ While Hattori *et al.*^[@bib9]^ did not examine the onset of chondrocyte hypertrophy, at E14.5, using their *Sox9* over-expressing mutants; our Prx1Cre transgene induced *Sox9* heterozygous mutant mice demonstrate accelerated hypertrophy via the down-regulation of *Sox9.* Therefore, our data are consistent with a specific role for SOX9 in regulating the onset of chondrocyte hypertrophy. Based on these data and our understanding of Notch signaling, we explored the genetic relationship between Notch signaling and *Sox9* in the context of chondrocyte hypertrophy. While the delayed onset of chondrocyte hypertorphy due to loss of RBPjk could be fully rescued by the removal of a single allele of *Sox9*, the same was not true concerning delayed terminal chondrocyte maturation. As we have suggested, it is therefore not likely that *Sox9* is involved in RBPjk-dependent Notch regulation of terminal chondrocyte hypertrophy, however, we cannot rule out the possibility that removal of a single allele of *Sox9* was not significant enough of a knock-down to effect the terminal chondrocyte maturation phenotype. In our current genetic model utilizing the *Prx1Cre*, removal of both *Sox9* alleles was impossible, as SOX9 is required for condensation formation and early chondrogenesis.^[@bib6]^

Our data demonstrate that haploinsufficiency of *Sox9* results in significant shortening and bowing of the endochondral elements. These data are consistent with previously reported *Sox9* mutants, including *Prx1Cre;Sox9^fx/+^* embryos analyzed by Akiyama *et al.*, which displayed hypoplasia and bowing of various endochondral elements.^[@bib6]^ Global haploinsufficiency of *Sox9* results in more severe limb element hypoplasia and bowing as compared to the *Prx1Cre* targeted *Sox9* mutants.^[@bib5]^ Interestingly, at E18.5, *Sox9* global heterozygous embryos display an approximately two-fold increase in the length of their hypertrophic zone. This expansion is likely due to early onset of hypertrophy, as opposed to the delays in terminal chondrocyte hypertrophy observed in Notch loss-of-function mutants.^[@bib5],[@bib18; @bib19; @bib20]^ An extension of the hypertrophic zone due to early onset in chondrocyte hypertrophy has been previously reported in β-catenin GOF embryos,^[@bib34]^ which has also been shown to down-regulate SOX9 during the transition to chondrocyte hypertrophy by specifically targeting SOX9 protein for proteosomal degradation.^[@bib35]^ Here, we demonstrated that complete removal of RBPjk-dependent Notch signaling in the *Sox9* haploinsufficient background was enough to restore some *Sox9* expression and promote cartilage growth similar to that observed in *Rbpjk* mutants, but not enough to correct the bowing observed in all *Sox9* haploinsufficient mutants.

In recent work using the *Col2Cre* transgene to study RBPjk-dependent and --independent Notch signaling effects on vertebral formation, Chen *et al.* proposed a model whereby RBPjk-dependent Notch signaling suppression of *Sox9* is important for normal axial skeletogenesis.^[@bib36]^ Controversially, they proposed a mechanism by which the NICD-RBPjk complex directly inhibits *Sox9* gene expression via direct binding to the *Sox9* promoter. While provocative, there is no evidence to suggest NICD-RBPjk complexes can function as transcriptional repressors since NICD recruitment to RBPjk and DNA is known to displace transcriptional repressors ultimately leading to transcriptional activation. Chen *et al.* provided chromatin immunoprecipitation (ChIP) assays detecting the recruitment of the NICD-RBPjk complex to RBPjk binding sites in the *Sox9* promoter as evidence of their claim. While it is possible and probable that NICD-RBPjk complexes bind to the *Sox9* promoter, it is more likely that NICD-RBPjk may have a physiological role in directly promoting *Sox9* expression in specific contexts. This is supported by data that demonstrate the ability of Notch to induce *Sox9* gene expression in embryonic stem cells, pancreatic cells, and Müller glial cells.^[@bib37; @bib38; @bib39]^ Furthermore, the work presented here in chondrogenic cells demonstrates that site specific mutations of the RBPjk binding site (proposed by Chen *et al*. as the repressive element) does not yield any change in Notch-mediated suppression of *Sox9*. Alternatively, we propose that Notch signaling leads to an indirect suppression of *Sox9* via the induction of alternative downstream targets. This is also supported by our own data, which demonstrates that Notch-induced inhibition of *Sox9* in chondrogenic cells requires active protein synthesis. We therefore hypothesize that one or more of the HES/HEY family of repressive bHLH transcription factors, some of the primary downstream targets of RBPjk-dependent Notch signaling, act as mediators of Notch signaling to repress *Sox9* gene expression. This is further supported by the loss of Notch-mediated suppression of *Sox9* driven luciferase activity when the *Sox9* promoter was truncated to exclude a putative HES/HEY binding site. Further studies will be required to elucidate the exact role HES/HEY factors may play in specifically regulating *Sox9* expression and cartilage development.
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![Loss of RBPjk leads to inappropriate expression of SOX9 in hypertrophic chondrocytes. Immunohistochemistry for SOX9 in control (**a**) and *Prx1Cre;Rbpjk^f/f^*(**b**) E14.5 humerus sections.](boneres201521-f1){#fig1}

![Notch regulates the onset of chondrocyte hypertrophy via *Sox9*. (**a**) Histological analyses of control (**a1**), *Prx1Cre;Rbpjk^f/f^* (**a2**), *Prx1Cre;Rbpjk^f/+^;Sox9^f/+^* (**a3**), *Prx1Cre;Rbpjk^f/f^;Sox9^f/+^* (**a4**), as well as, control (**a5**) and *Prx1Cre;Sox9^f/+^* embryonic tibia sections at E14.5. (**b**) Quantification of the lengths of the hypertrophic zone, expressed as a percentage of the total length of the element. (**b1**) WT **--** wild-type, *Rbpjk* (*Prx1Cre;Rbpjk^f/f^*), Dbl Het (*Prx1Cre;Rbpjk^f/+^;Sox9^f/+^*), RBPJk; Sox9 (*Prx1Cre;Rbpjk^f/f^;Sox9^f/+^*). (**b2**) WT **--** wild-type, Sox9 Het (*Prx1Cre;Sox9^f/+^*).](boneres201521-f2){#fig2}

![Notch regulates the onset of chondrocyte hypertrophy via *Sox9*. Histological and molecular analysis of control, *Prx1Cre;Rbpjk^f/f^* and *Prx1Cre;Rbpjk^f/f^;Sox9^f/+^* embryonic tibia sections at E14.5. ABH/OG staining (**a, b, c**). *In situ* hybridization for markers of chondrocyte maturation -- *Indian Hedgehog* (*Ihh*) (**d, e, f**), *Collagen 10a1* (*Col10a1*) (**g, h, i**) and *Matrix Metaloproteinase 13* (*Mmp13*) (**j, k, l**). Yellow arrowheads indicate primary *Ihh* expressing domains. Yellow double-headed arrows indicate *Col10a1* expression domain. Orange circle highlights *Mmp13* expression.](boneres201521-f3){#fig3}

![Cartilage element length reduction due to *Sox9* haploinsufficiency is rescued by loss of RBPjk-dependent Notch signaling. (**a**) ABH/OG staining of control (**a1**), *Prx1Cre;Rbpjk^f/f^* (**a2**), *Prx1Cre;Rbpjk^f/+^*;*Sox9^f/+^* (**a3**) and *Prx1Cre;Rbpjk^f/f^*;*Sox9^f/+^* (**a4**) E18.5 full length tibia sections. (**b**) ABH/OG staining of control (**b1**) and *Prx1Cre*;*Sox9^f/+^* (**b2**) E18.5 tibia sections. (**c**) Quantification of the size difference of E18.5 tibia sections.](boneres201521-f4){#fig4}

![Notch regulation of terminal chondrocyte maturation is not likely to be mediated via *Sox9*. (**a**) Histological and molecular analysis of control, *Prx1Cre;RBPjk^f/f^***,***Prx1Cre;RBPjk^f/f^***;***Sox9^f/+^* embryonic tibia sections at E18.5. ABH/OG staining (**a1**--**a3**). Markers of chondrocyte maturation -- *Indian Hedgehog* (*Ihh*) (**a4**--**a6**), *Collagen 10a1* (*Col10a1*) (**a7**--**a9**) and *Matrix Metaloproteinase 13* (*Mmp13*) (**a10**--**a12**) were analyzed by *in situ* hybridization. (**b**) Immunohistochemistry for SOX9 in control (**b1**), *Prx1Cre;RBPjk^f/f^* (**b2**), and *Prx1Cre;RBPjk^f/f^*;*Sox9^f/+^* (**b3**) embryonic tibia sections at E18.5. Yellow double-headed arrows indicate the length of the SOX9 expressing hypertrophic chondrocyte domain. Red double-headed arrows indicate the total length of the hypertrophic zone.](boneres201521-f5){#fig5}

![Notch signaling inhibits *Sox9* gene expression via secondary effectors. (**a**) Diagram for the localization of a RBPjk consensus binding site (yellow box is wild-type sequence and blue box is mutant sequence) and N-box consensus binding site (red box) in the *Sox9* promoter and luciferase constructs. Core consensus sequences are listed in diagram. (**b**) ATDC5 cells were co-transfected with Flag or NICD1 over-expression vectors and either a wild-type 6.8 kb *Sox9*-Luciferase complex (**−**6.8 kb WT) or 6.8 kb construct with a mutated RBPjk binding site (−6.8 kb MT). Luciferase levels were measured 24 hours after transfection. (**c**) ATDC5 cells were co-transfected with Flag or NICD1 over-expression vectors and either a 1 kb, 0.5 kb, or 0.32 kb *Sox9*-Luciferase deletion constructs. Luciferase levels were measured 24 hours after transfection. (**d**) Quantitative RT-PCR assessing *Hes1* (**d1, d2**), *Hey1* (**d3, d4**), and *Sox9* (**d5, d6**) gene expression in ATDC5 cells at 0-, 2-, 4-, and 8-hour post-culture on IgG versus JAG1 coated plates in the absence (**d1, d3, d5**) or presence (**d2, d4, d6**) of cycloheximide.](boneres201521-f6){#fig6}
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